How Cutaneous Lymphoma Patients May Be Impacted by COVID-19 Vaccines

Susan Thornton, CEO of Cutaneous Lymphoma Foundation, discusses how the cutaneous lymphoma community may be impacted by potential COVID-19 vaccines.

Cutaneous lymphoma is a rare subtype of non-Hodgkin lymphoma that primarily affects the skin. Cutaneous lymphoma can originate in B-cells (i.e., cutaneous B-cell lymphoma); however, cutaneous T-cell lymphoma (CTCL) is more common. There are many forms of CTCL but mycosis fungoides and Sézary syndrome are the most common and most severe.

Ms. Thornton noted that since COVID-19 vaccines and treatments target the immune system and CTCL is a cancer of the immune system, this is a potential concern for the patient community. Nevertheless, Ms. Thornton remains optimistic that COVID-19 treatment options available for cutaneous lymphoma patients will become available.

To learn more about cutaneous lymphoma and other rare cancers, visit checkrare.com/diseases/cancers/.